Lucy Sim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lucy Sim has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Adrian Gibbs
Radiation Oncology Princess Alexandra Hospital Raymond Terrace (ROPART) Brisbane Queensland Australia
2 shared publications- Andrew Pullar
Radiation Oncology Princess Alexandra Hospital Raymond Terrace (ROPART) Brisbane Queensland Australia
2 shared publications - Gishan Ratnayake
Department of Radiation Oncology, Princess Alexandra Hospital , Brisbane 4102, Australia
2 shared publications - Lotte S. Fog
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) Sydney New South Wales Australia
2 shared publications - Robyn Cheuk
Radiation Oncology Princess Alexandra Hospital Raymond Terrace (ROPART) Brisbane Queensland Australia
2 shared publications - Sarah Li
Radiation Oncology Princess Alexandra Hospital Raymond Terrace (ROPART) Brisbane Queensland Australia
2 shared publications
Latest Publications
- 16 November 2026
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
Protons should be standard of care for choroidal melanoma
- 16 November 2026
- Published by Springer Nature in Physical and Engineering Sciences in Medicine
Protons should be standard of care for choroidal melanoma
- 7 October 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Choroidal Melanoma Treated With Ruthenium‐106 Eye Plaque Brachytherapy: Results of an Australian Statewide Service From November 2020 to January 2025
Introduction: Uveal melanoma is a rare but aggressive malignancy, predominantly affecting the choroid. This study is the first retrospective review performed on adult choroidal melanoma patients treated with Ruthenium‐106 plaque brachytherapy in Queensland. Method: The study period was November 2020 to January 2025, where patient, tumour, and treatment factors, as well as local control, salvage treatments, radiation retinopathy, and visual acuity were assessed at 6, 12, 24, and 36 months post‐treatment. Results: A total of 151 patients with a mean tumour thickness of 3.85 mm and mean largest basal diameter of 10.2 mm received treatment. A dose of 100 Gy to the tumour apex was prescribed to 88.7% of patients. The short‐term risk factor for disease progression was tumour thickness (odds ratio [OR] 2.01, 95% confidence interval [CI], 1.11–3.87; p = 0.025), whereas tumour to optic nerve distance was a protective factor in both the short‐ (OR 0.55, 95% CI 0.31–0.82; p = 0.013) and long‐term (OR 0.75, 95% CI 0.60–0.90; p = 0.005). At 36 months post‐treatment, local control was 89.5%, the enucleation rate was 3.3%, tumour thickness (OR 1.77, 95% CI 1.1–2.98; p = 0.022) and sclera dose (OR 1.01, 95% CI 1–1.01; p = 0.045) were risk factors for severe radiation retinopathy. Median visual acuity decreased by one Snellen chart line. When tumour distance to optic nerve or foveola is greater than 3 mm, there was minimal change to visual acuity. Conclusion: The findings demonstrate that high‐quality plaque brachytherapy can be delivered effectively at a statewide level.
- 7 October 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Choroidal Melanoma Treated With Ruthenium‐106 Eye Plaque Brachytherapy: Results of an Australian Statewide Service From November 2020 to January 2025
Introduction: Uveal melanoma is a rare but aggressive malignancy, predominantly affecting the choroid. This study is the first retrospective review performed on adult choroidal melanoma patients treated with Ruthenium‐106 plaque brachytherapy in Queensland. Method: The study period was November 2020 to January 2025, where patient, tumour, and treatment factors, as well as local control, salvage treatments, radiation retinopathy, and visual acuity were assessed at 6, 12, 24, and 36 months post‐treatment. Results: A total of 151 patients with a mean tumour thickness of 3.85 mm and mean largest basal diameter of 10.2 mm received treatment. A dose of 100 Gy to the tumour apex was prescribed to 88.7% of patients. The short‐term risk factor for disease progression was tumour thickness (odds ratio [OR] 2.01, 95% confidence interval [CI], 1.11–3.87; p = 0.025), whereas tumour to optic nerve distance was a protective factor in both the short‐ (OR 0.55, 95% CI 0.31–0.82; p = 0.013) and long‐term (OR 0.75, 95% CI 0.60–0.90; p = 0.005). At 36 months post‐treatment, local control was 89.5%, the enucleation rate was 3.3%, tumour thickness (OR 1.77, 95% CI 1.1–2.98; p = 0.022) and sclera dose (OR 1.01, 95% CI 1–1.01; p = 0.045) were risk factors for severe radiation retinopathy. Median visual acuity decreased by one Snellen chart line. When tumour distance to optic nerve or foveola is greater than 3 mm, there was minimal change to visual acuity. Conclusion: The findings demonstrate that high‐quality plaque brachytherapy can be delivered effectively at a statewide level.
- Open Access
- 27 May 2026
- Published by Elsevier in Materials Today Advances
- Vol. 30
Impact of hypofractionated radiotherapy on 3D breast cancer models
- 27 May 2026
- Published by Elsevier in Materials Today Advances
- Vol. 30
Open AccessImpact of hypofractionated radiotherapy on 3D breast cancer models
- Open Access
- 21 March 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 219, 111493
It’s not your device, it’s how you use it – Sensitivity and specificity of PSQA devices in the SEAFARER head and neck study
- 21 March 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 219, 111493
Open AccessIt’s not your device, it’s how you use it – Sensitivity and specificity of PSQA devices in the SEAFARER head and neck study
- 14 February 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 70 (3) , 322-330
Total Body Irradiation in Australia and New Zealand: A 2024 Practice Survey on Changing Patterns of Care
Introduction: Total body irradiation (TBI) practice varies globally. The optimal technique for TBI has not yet been determined, although guidelines and recommendations are available. Five years after the initial Australia and New Zealand (ANZ) practice survey in 2019, we report updated 2024 TBI practice patterns from 19 ANZ centres who are members of the ANZ Transplant and Cellular Therapies (ANZTCT) TBI Special Interest Group (TBISIG). Method: The 2024 survey was distributed in November 2024. Survey questions covered patient cohorts and caseloads, TBI regimens and dose‐fractionations, TBI techniques, planning considerations, quality assurance, and treatment delivery. For all centres, one staff member from each discipline (Radiation Oncology, Medical Physics, and Radiation Therapy) was invited to respond. Results: Responses were received from all 19 centres. Seven centres use modulated techniques in 2024, whereas only one centre delivered modulated TBI in 2019. Twelve centres use large open fields in 2024, six of which are considering changing to volumetric modulated arc therapy (VMAT) TBI. Compared to large open fields, modulated techniques (1) require dedicated patient immobilisation equipment and treatment planning software, (2) reduce dose to organs at risk (such as lungs and kidneys) below the prescription dose, (3) have higher dose rates, and (4) require more time for planning and treatment delivery. Conclusion: The 2024 survey showed diverse TBI practice patterns in ANZ. Compared to 2019, more centres are using or actively considering the implementation of modulated techniques, such as VMAT TBI, which adds to the complexity of treatment planning and delivery.
- 14 February 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 70 (3) , 322-330
Total Body Irradiation in Australia and New Zealand: A 2024 Practice Survey on Changing Patterns of Care
Introduction: Total body irradiation (TBI) practice varies globally. The optimal technique for TBI has not yet been determined, although guidelines and recommendations are available. Five years after the initial Australia and New Zealand (ANZ) practice survey in 2019, we report updated 2024 TBI practice patterns from 19 ANZ centres who are members of the ANZ Transplant and Cellular Therapies (ANZTCT) TBI Special Interest Group (TBISIG). Method: The 2024 survey was distributed in November 2024. Survey questions covered patient cohorts and caseloads, TBI regimens and dose‐fractionations, TBI techniques, planning considerations, quality assurance, and treatment delivery. For all centres, one staff member from each discipline (Radiation Oncology, Medical Physics, and Radiation Therapy) was invited to respond. Results: Responses were received from all 19 centres. Seven centres use modulated techniques in 2024, whereas only one centre delivered modulated TBI in 2019. Twelve centres use large open fields in 2024, six of which are considering changing to volumetric modulated arc therapy (VMAT) TBI. Compared to large open fields, modulated techniques (1) require dedicated patient immobilisation equipment and treatment planning software, (2) reduce dose to organs at risk (such as lungs and kidneys) below the prescription dose, (3) have higher dose rates, and (4) require more time for planning and treatment delivery. Conclusion: The 2024 survey showed diverse TBI practice patterns in ANZ. Compared to 2019, more centres are using or actively considering the implementation of modulated techniques, such as VMAT TBI, which adds to the complexity of treatment planning and delivery.
- Open Access
- 22 April 2022
- Published by Wiley in Journal of Medical Radiation Sciences
- Vol. 69 (3) , 357-366
Modified volumetric modulated arc therapy technique with reduced planning and treatment time for craniospinal irradiation utilising two isocentres
Introduction: Paediatric patients (individuals below 18 years of age) requiring cranial‐spinal irradiation (CSI) at our institution are commonly planned and treated using a three isocentre (3‐ISO) volumetric modulated arc therapy (VMAT) technique. A modified two isocentre (2‐ISO) VMAT technique was investigated with the aim to improve workflow and reduce planning and treatment time.Methods: Five CSI paediatric patients previously treated with a 3‐ISO VMAT technique were retrospectively replanned using a 2‐ISO VMAT technique. The 2‐ISO VMAT plans were reviewed and approved by a radiation oncologist (RO) before undergoing patient‐specific quality assurance (QA) procedures, performed by a radiation oncology medical physicist (ROMP). Planning target volume (PTV) coverage, organ‐at‐risk (OAR) dose as well as planning and treatment durations of the first five patients utilising 2‐ISO technique were compared with 3‐ISO technique.Results: The average percentage difference in PTV coverage by 95% reference dose between the 2‐ISO and 3‐ISO is 0.14%, and the average difference in OAR median dose is 0.68 Gy. Conformity and homogeneity indices have the same averages at 1.18 and 0.4 respectively. Patient‐specific physics QA results were all comparable with the 3‐ISO averages at 98.84% and the 2‐ISO at 98.71%. Planning duration for the 2‐ISO was reduced by up to 75%, and daily treatment duration was reduced by up to 50%. Of all the previously treated CSI patients using a 3‐ISO technique, 45% were suitable for the 2‐ISO technique.Conclusion: The 2‐ISO VMAT technique provided comparable dose distribution based on PTV coverage, OAR dose and plan metric indices. Reduced planning and treatment duration with the 2‐ISO technique facilitated improved workflow with decreased sedation time for paediatric patients requiring a general anaesthesia.
- 22 April 2022
- Published by Wiley in Journal of Medical Radiation Sciences
- Vol. 69 (3) , 357-366
Open AccessModified volumetric modulated arc therapy technique with reduced planning and treatment time for craniospinal irradiation utilising two isocentres
Introduction: Paediatric patients (individuals below 18 years of age) requiring cranial‐spinal irradiation (CSI) at our institution are commonly planned and treated using a three isocentre (3‐ISO) volumetric modulated arc therapy (VMAT) technique. A modified two isocentre (2‐ISO) VMAT technique was investigated with the aim to improve workflow and reduce planning and treatment time.Methods: Five CSI paediatric patients previously treated with a 3‐ISO VMAT technique were retrospectively replanned using a 2‐ISO VMAT technique. The 2‐ISO VMAT plans were reviewed and approved by a radiation oncologist (RO) before undergoing patient‐specific quality assurance (QA) procedures, performed by a radiation oncology medical physicist (ROMP). Planning target volume (PTV) coverage, organ‐at‐risk (OAR) dose as well as planning and treatment durations of the first five patients utilising 2‐ISO technique were compared with 3‐ISO technique.Results: The average percentage difference in PTV coverage by 95% reference dose between the 2‐ISO and 3‐ISO is 0.14%, and the average difference in OAR median dose is 0.68 Gy. Conformity and homogeneity indices have the same averages at 1.18 and 0.4 respectively. Patient‐specific physics QA results were all comparable with the 3‐ISO averages at 98.84% and the 2‐ISO at 98.71%. Planning duration for the 2‐ISO was reduced by up to 75%, and daily treatment duration was reduced by up to 50%. Of all the previously treated CSI patients using a 3‐ISO technique, 45% were suitable for the 2‐ISO technique.Conclusion: The 2‐ISO VMAT technique provided comparable dose distribution based on PTV coverage, OAR dose and plan metric indices. Reduced planning and treatment duration with the 2‐ISO technique facilitated improved workflow with decreased sedation time for paediatric patients requiring a general anaesthesia.
- 1 December 2021
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 189
Investigation of scattered dose in a mouse phantom model for pre-clinical dosimetry studies
- 1 December 2021
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 189
Investigation of scattered dose in a mouse phantom model for pre-clinical dosimetry studies
- 11 October 2016
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 39 (4) , 863-870
Novel application of 3D printing in brachytherapy using MED610 3D printed insert for I-125 ROPES eye plaque
The purpose of this study was to evaluate if MED610 3D printed material can be used as a surrogate for acrylic in the manufacturing of a replacement insert used in an eye plaque brachytherapy applicator. Measurement of the dose distributions from a standard acrylic insert were compared with dose obtained from MED610 3D printed replica using GafChromic® EBT3 films. The study used a 15 mm Radiation Oncology Physics and Engineering Services, Australia (ROPES) type eye plaque applicator loaded with I-125 (model 6711) seeds. GafChromic® EBT3 films were placed in a solid water phantom and dose distributions were measured three-dimensionally both along and perpendicular to a loaded ROPES eye plaque’s central axis (CAX). Each measurement was performed with the stainless steel plaque backing attached to the eye plaque, to assess the variability of the dose distributions between the acrylic and MED 610 insert. Results of dose along the central axis were compared between acrylic and MED610 insert and the results found agreement within 1.5 %. Off-axis profiles were also compared between the acrylic insert and MED610 and were found to agree to within 7 % in the central 15 mm width centred on CAX at depths ranging from z = 2 mm to z = 8 mm in 2 mm increments. The aim of this investigation was to verify the consistency between doses profiles over a range of clinically relevant depths for a 15 mm loaded ROPES plaque using acrylic versus MED610 material. The results show an agreement between experimental measurements given the film uncertainty of 7 %.
- 11 October 2016
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 39 (4) , 863-870
Novel application of 3D printing in brachytherapy using MED610 3D printed insert for I-125 ROPES eye plaque
The purpose of this study was to evaluate if MED610 3D printed material can be used as a surrogate for acrylic in the manufacturing of a replacement insert used in an eye plaque brachytherapy applicator. Measurement of the dose distributions from a standard acrylic insert were compared with dose obtained from MED610 3D printed replica using GafChromic® EBT3 films. The study used a 15 mm Radiation Oncology Physics and Engineering Services, Australia (ROPES) type eye plaque applicator loaded with I-125 (model 6711) seeds. GafChromic® EBT3 films were placed in a solid water phantom and dose distributions were measured three-dimensionally both along and perpendicular to a loaded ROPES eye plaque’s central axis (CAX). Each measurement was performed with the stainless steel plaque backing attached to the eye plaque, to assess the variability of the dose distributions between the acrylic and MED 610 insert. Results of dose along the central axis were compared between acrylic and MED610 insert and the results found agreement within 1.5 %. Off-axis profiles were also compared between the acrylic insert and MED610 and were found to agree to within 7 % in the central 15 mm width centred on CAX at depths ranging from z = 2 mm to z = 8 mm in 2 mm increments. The aim of this investigation was to verify the consistency between doses profiles over a range of clinically relevant depths for a 15 mm loaded ROPES plaque using acrylic versus MED610 material. The results show an agreement between experimental measurements given the film uncertainty of 7 %.
- 17 August 2014
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 37 (3) , 559-566
The variation of HVL with focal spot to chamber distance as a function of beam quality for the Pantak Therapax 150 X-ray unit and the implications on dose to water determination using the IPEMB code of practice
Using a Pantak Therapax SXT 150 system HVL values for clinical beams generated with filters 4–8, were determined as a function of FCD (30–130 cm). Aluminium absorbers were placed midway between the focus and chamber with collimation to define both narrow and broad beam geometries. For filters 4–7 with broad beam geometry the HVL initially decreases as the FCD is increased from 30 cm and then increases as the FCD approaches 130 cm. In contrast filter 8 exhibits a reduction in HVL with increasing FCD attributed to the decreasing influence of absorber scatter. With narrow beam geometry the HVL of filter 4 increases as the FCD is increased. For other filters the HVL variation is similar to that for the broader beam albeit that for a given FCD the HVL is smaller, a consequence of reduced absorber scatter. Monte Carlo BEAMnrc simulations of filter 4–8 beams demonstrated a quality dependent air attenuation effect associated with an increase in HVL for lower quality beams with increasing FCD. Thus for the beams investigated in this work the variation of HVL with FCD can be interpreted in terms of the competing influences of absorber scatter, which tends to decrease the measured HVL, and a quality dependent in air attenuation that tends to increase the HVL with increasing FCD. In terms of an absorbed dose determination it is shown that changes of HVL with FCD resulted in variations of D w,z = 0 < ±0.5 %.
- 17 August 2014
- Published by Springer Nature in Australasian Physics & Engineering Sciences in Medicine
- Vol. 37 (3) , 559-566
The variation of HVL with focal spot to chamber distance as a function of beam quality for the Pantak Therapax 150 X-ray unit and the implications on dose to water determination using the IPEMB code of practice
Using a Pantak Therapax SXT 150 system HVL values for clinical beams generated with filters 4–8, were determined as a function of FCD (30–130 cm). Aluminium absorbers were placed midway between the focus and chamber with collimation to define both narrow and broad beam geometries. For filters 4–7 with broad beam geometry the HVL initially decreases as the FCD is increased from 30 cm and then increases as the FCD approaches 130 cm. In contrast filter 8 exhibits a reduction in HVL with increasing FCD attributed to the decreasing influence of absorber scatter. With narrow beam geometry the HVL of filter 4 increases as the FCD is increased. For other filters the HVL variation is similar to that for the broader beam albeit that for a given FCD the HVL is smaller, a consequence of reduced absorber scatter. Monte Carlo BEAMnrc simulations of filter 4–8 beams demonstrated a quality dependent air attenuation effect associated with an increase in HVL for lower quality beams with increasing FCD. Thus for the beams investigated in this work the variation of HVL with FCD can be interpreted in terms of the competing influences of absorber scatter, which tends to decrease the measured HVL, and a quality dependent in air attenuation that tends to increase the HVL with increasing FCD. In terms of an absorbed dose determination it is shown that changes of HVL with FCD resulted in variations of D w,z = 0 < ±0.5 %.